{"id":"W4213238101","doi":"10.1200/jco.2022.40.6_suppl.346","title":"Efficacy of tyrosine kinase inhibitors (TKI) after combination ipilimumab plus nivolumab (I/N) in metastatic clear cell renal cell carcinoma (ccmRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Université Laval; McMaster University; University of Ottawa; Sunnybrook Hospital; BC Cancer Agency; Hôtel-Dieu de Québec; Princess Margaret Cancer Centre; University of Calgary; Juravinski Cancer Centre; University of Manitoba; Dalhousie University; University Health Network; University of British Columbia; University of Alberta","funders":"","keywords":"Medicine; Sunitinib; Pazopanib; Discontinuation; Nivolumab; Renal cell carcinoma; Internal medicine; Ipilimumab; Oncology; Tyrosine-kinase inhibitor; Cabozantinib; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006951636,0.000207764,0.000523584,0.0003957792,0.0002009522,0.0004030936,0.0002427137,0.0002824379,0.0007241088],"category_scores_gemma":[0.001031373,0.00009236069,0.0007937109,0.0005378059,0.0001500011,0.000286701,0.0001959604,0.0004179583,0.0001208647],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00124284,"about_ca_system_score_gemma":0.0007533155,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01357537,"about_ca_topic_score_gemma":0.02831642,"domain_scores_codex":[0.9996893,0.00005401751,0.0000323272,0.0000701737,0.00009162236,0.00006250462],"domain_scores_gemma":[0.9991724,0.0001629121,0.0003227598,0.00003186193,0.00008558918,0.000224414],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02839423,0.0007045671,0.9011664,0.0003515419,0.0009138116,0.0001881221,0.0001051938,0.001171681,0.002508441,0.00002958045,0.001367806,0.06309871],"study_design_scores_gemma":[0.0007663947,0.009304213,0.9858195,0.00003716431,0.0006692976,0.0003719946,0.0000490939,0.0008984834,0.000829415,0.0000189866,0.001221932,0.00001358067],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995505,0.002897622,0.00004134878,0.00005218687,0.00001125192,0.00002884436,0.0008913254,0.000008864743,0.0005635241],"genre_scores_gemma":[0.9983662,0.0003822523,0.00005067392,0.00002938667,0.00001117071,0.000008972175,0.001035456,0.000001263121,0.000114588],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9864246,"threshold_uncertainty_score":0.02699274,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04212863513743546,"score_gpt":0.3229918578124641,"score_spread":0.2808632226750286,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}